NCT04701164 - Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | Biotech Hunter

Enrollment

242

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

April 20, 2024

Study Completion Date

April 20, 2024

Conditions

Guillain-Barre Syndrome

Interventions

DRUG

ANX005

Solution for intravenous infusion

DRUG

Placebo

Solution for intravenous infusion

Trial Locations (11)

Dhaka Medical Center, Dhaka

National Institute of Neurosciences and Hospital (NINS), Dhaka

Baguio General Hospital Medical Center, Baguio City

Batangas Medical Center, Batangas

Mary Mediatrix Medical Center, Batangas

Perpetual Succour Hospital, Cebu City

Cotabato Regional Medical Center, Cotabato City

Southern Philippines Medical Center, Davao City

Jose R. Reyes Memorial Medical Center, Manila

West Visayas State University Medical Center, Manila

Zamboanga City Medical Center, Zamboanga City

All Listed Sponsors

lead

Annexon, Inc.

INDUSTRY